MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmjgast-2025-002153

Медицинская библиотека · BMJ open gastroenterology · 2026

Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis.

Hart Amy, Sridhar Sunandini, Venkat Swati, Lee Tae, Rusbuldt Joshua J, Richards Dylan, Sisk Christopher, Horowitz Dan, Tomsho Lynn, Kannan Arun K, Ruane Darren, Van den Berge Koen, Rubin David T, Sands Bruce E, De Hertogh Gert, Huang Kuan-Hsiang G, Germinaro Matthew, Cua Dan, Waterworth Dawn, Freeman Tom C, Vetter Marion L, McRae Bradford, Verstockt Bram, Branigan Patrick

СтатьяРандомизированное исследованиеКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

OBJECTIVE

Selective inhibition of interleukin (IL)-23 through antagonism of the IL-23p19 subunit has demonstrated clinical efficacy in inflammatory bowel disease, but the molecular changes underlying the efficacy outcomes have not yet been described. Here, we provide a detailed evaluation of the cellular and molecular changes associated with guselkumab treatment in patients with moderately to severely active ulcerative colitis (UC) from the QUASAR Phase IIb induction study.

METHODS

In this double-blind, placebo-controlled, dose-ranging induction study, patients (n=313) were randomised (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0, 4, and 8. Colon biopsy samples were collected at weeks 0 and 12, enabling molecular profiling by bulk RNA sequencing (RNA-seq, n=257), single-cell RNA sequencing (n=52), and flow cytometry (n=30). Serum proteomic profiling was also performed at weeks 0, 4, and 12 (n=302).

RESULTS

Guselkumab treatment significantly reduced pro-inflammatory serum proteins by week 4 with continued decline through week 12, compared with placebo. Unsupervised analysis of tissue gene modules revealed significant changes in transcriptional states related to pro-inflammatory and epithelial repair pathways, which were most pronounced in patients who achieved histological-endoscopic mucosal improvement (HEMI) at week 12, an important tissue-based end point. Single-cell analyses supported a decrease in the cellular abundance of pro-inflammatory and an increase in mucosal cell types in tissue following treatment.

CONCLUSION

This analysis of guselkumab in UC demonstrated changes in key pathways and cell types that are associated with achieving important clinical end points including HEMI at week 12.

TRIAL REGISTRATION NUMBER: NCT04033445.

Для цитирования: Hart Amy, Sridhar Sunandini, Venkat Swati, Lee Tae, Rusbuldt Joshua J, Richards Dylan, Sisk Christopher, Horowitz Dan, Tomsho Lynn, Kannan Arun K, Ruane Darren, Van den Berge Koen, Rubin David T, Sands Bruce E, De Hertogh Gert, Huang Kuan-Hsiang G, Germinaro Matthew, Cua Dan, Waterworth Dawn, Freeman Tom C, Vetter Marion L, McRae Bradford, Verstockt Bram, Branigan Patrick. Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis.. BMJ open gastroenterology. 2026. DOI: 10.1136/bmjgast-2025-002153.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.